Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00326768
First received: May 16, 2006
Last updated: November 11, 2013
Last verified: November 2013

May 16, 2006
November 11, 2013
May 2006
August 2007   (final data collection date for primary outcome measure)
  • Incidence of adverse events [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Changes in clinical laboratory tests (haematology, blood chemistry and urinalysis) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Changes in electrocardiogram (ECG) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Changes in blood pressure and pulse rate [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
The primary endpoint is safety of 52 weeks of open-label treatment.
Complete list of historical versions of study NCT00326768 on ClinicalTrials.gov Archive Site
  • Seated Diastolic Blood Pressure (DBP) control rate [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Seated Systolic Blood Pressure (SBP) control rate [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Seated DBP response rate [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Seated SBP response rate [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Seated blood pressure (BP) normality criteria [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Changes in seated DBP [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
  • Changes in seated SBP [ Time Frame: after 12 and 52 weeks ] [ Designated as safety issue: No ]
The secondary endpoint is efficacy after 12 weeks of combination treatment.
Not Provided
Not Provided
 
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation

The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and telmisartan 40 mg plus HCTZ 12.5 mg in patients with essential hypertension.

This is a multi-centre study with three centres participating with a target of 30 to 90 patients entering the maintenance period and 20-60 patients completing long-term treatment per centre. The recruitment period will be about three months from the start of the study.

Study Hypothesis:

The primary objective of this study is to demonstrate the long-term safety of a fixed dose combination of telmisartan/HCTZ fixed-dose combination treatment. This study has no control group; therefore, no hypothesis testing will be performed.

Comparison(s):

This study has no control group.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypertension
  • Drug: Telmisartan 40 mg/HCTZ 12.5 mg
  • Drug: Telmisartan 40 mg
  • Drug: Telmisartan 80 mg/HCTZ 12.5 mg
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
184
August 2007
August 2007   (final data collection date for primary outcome measure)
  1. Essential hypertensive patients who meet the following criteria:

    • In case of using any antihypertensives, mean seated DBP* must be over 90 and under 114 mmHg at Visit 1
    • In case of not using any antihypertensives, mean seated DBP* must be over 95 and under 114 mmHg at Visit 1
    • Mean seated DBP* must be over 90 at Visit 2 (* The mean DBP values will be calculated as the average of three seated measurements taken at two-minute intervals).
  2. Age over 20 and under 80 years at Visit 1 (Male or Female)
  3. Outpatient
  4. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications
  5. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.

1. Patients taking four or more anti-hypertensive medications at Visit 1 2. Patients with known or suspected secondary hypertension (renovascular hypertension, primary aldosteronism, pheochromocytoma, etc.) 3. Patients whose mean seated DBP > 114 mmHg and/or mean seated SBP > 200 mmHg at Visit 1, Visit 2 or Visit 3 4. Patients with sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias (AV-block II-III, atrial fibrillation etc.) 5. Patients with NYHA functional class heart failure III-IV 6. Patients with a history of myocardial infarction or cardiac surgery within last 6 3 months before signing the informed consent form 7. Patients with a history of coronary artery bypass surgery or percutaneous transluminal coronary angioplasty (PTCA) within last 3 months before signing the informed consent form 8. Patients with a history of unstable angina within last 3 months before signing the informed consent form 9. Patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve 10. Patients with a history of stroke or transient ischemic attack within last 6 months before signing the informed consent form 11. Patients with a history of sudden exacerbation of renal function with AT1 receptor antagonists or ACE inhibitors; post-renal transplant 12. Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with AT1 receptor antagonists or ACE inhibitors 13. Patients with known hypersensitivity to any component of the formulation, or a known hypersensitivity to sulfonamides or sulfonamide-derived drugs (e.g. thiazides) 14. Known, suspected or history of gout

Both
20 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00326768
502.516
Not Provided
Not Provided
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Study Coordinator Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP